June 24 (Reuters) - Alumis is targeting a valuation of

up to $1.01 billion in its initial public offering in the United

States, the therapy developer said on Monday.

Biotech IPOs have shown signs of a rebound this year, but a

string of poor post-debut performances have tempered

expectations of a full market recovery.

The company is looking to raise as much as $317.7 million by

offering nearly 17.7 million shares at a price range of $16 and

$18 each.

Alumis expects to list on the Nasdaq Global Market under the

symbol "ALMS".

Morgan Stanley, Leerink Partners, Cantor Fitzgerald and

Guggenheim Securities are the underwriters for the offering.